Abstract: A respiratory disease analytics system provides respiratory disease risk reports to a patient, provider, or third-party entity describing a patient's risk of experiencing a medication usage event given data in a geographic region. Regional data, including air pollutant conditions, weather conditions, demographic information, built environment factors, and regional health conditions for a geographic region are accessed from other sources and assigned based on event data recorded during a medicament usage event, as collected by sensors associated with the patient's medicament device/s. The regional data is assigned to medicament usage events occurring within a period of time. The assigned regional data is analyzed to determine an expected number of medication usage events for the geographic region occurring over the period of time.

Abstract: A secondary battery is provided for cycling between a charged and a discharged state, the secondary battery including a battery enclosure, an electrode assembly, carrier ions, a non-aqueous liquid electrolyte within the battery enclosure, and a set of electrode constraints. The set of electrode constraints includes a primary constraint system having first and second primary growth constraints and at least one primary connecting member, the first and second primary growth constraints separated from each other in the longitudinal direction, wherein the primary constraint array restrains growth of the electrode assembly in the longitudinal direction such that any increase in the Feret diameter of the electrode assembly in the longitudinal direction over 20 consecutive cycles of the secondary battery is less than 20%.

Abstract: Described here are devices, systems, and methods for closing the left atrial appendage. The methods described here utilize a closure device for closing the left atrial appendage and guides or expandable elements with ablation or abrading elements to ablate or abrade the left atrial appendage. In general, these methods include positioning a balloon at least partially within the atrial appendage, positioning a closure assembly of a closure device around an exterior of the atrial appendage, inflating the balloon, partially closing the closure assembly, ablating the interior tissue of the atrial appendage with the inflated balloon, removing the balloon from the atrial appendage, and closing the atrial appendage with the closure assembly.

Abstract: A tape applicator including a housing and an adjustment mechanism. The housing partially defines a cavity. The adjustment mechanism includes a course and an adjustment plate. The course includes a plurality of positions. The adjustment plate is movable along the course among the plurality of positions. The adjustment plate is held in a selected position of the plurality of positions by the housing based on a size of a tape roll configured to be supported in the cavity.

Abstract: The invention relates to the inhibition of mutant KRAS sequences using RNA interference (RNAi). In addition, the present invention provides lipid nanoparticle (LNP) compositions as delivery vehicles for RNAi agents and methods of administering them for therapeutic purposes.

Abstract: The invention provides methods and compositions for assaying infectivity of viruses and potential treatments of such viruses in the upper respiratory tract using an air-liquid interface model with nasal epithelium cells; and treatment of viral infections of the upper respiratory tract by treating with bitter taste receptor agonists that stimulate NO production and/or antimicrobial protein production.

Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.

Abstract: The invention provides methods and compositions for assaying infectivity of viruses and potential treatments of such viruses in the upper respiratory tract using an air-liquid interface model with nasal epithelium cells; and treatment of viral infections of the upper respiratory tract by treating with bitter taste receptor agonists that stimulate NO production and/or antimicrobial protein production.

Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.

Abstract: Disclosed herein are methods and compositions for treating multiple myeloma, and for enhancing antibody-dependent cellular toxicity (ADCC). Specifically, disclosed herein are methods of using antagonists of the aryl hydrocarbon receptor (AHR) to treat multiple myeloma and enhance ADCC. Also specifically disclosed is liposomal CH233191.

Abstract: Methods for inhibiting oligonucleotide activity in vitro or in vivo to a cell that are formulated with at least one oligonucleotide encapsulated in a lipid nanoparticle are disclosed.

Abstract: Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed.

Abstract: Methods for inhibiting oligonucleotide activity in vitro or in vivo to a cell that are formulated with at least one oligonucleotide encapsulated in a lipid nanoparticle are disclosed.

Abstract: Lipid nanoparticle formulations, methods of making, and methods of using same are disclosed.

Abstract: Compositions for inhibiting oligonucleotide activity in vitro or in vivo to a cell that are formulated with at least one oligonucleotide encapsulated in a lipid nanoparticle, methods of making, and methods of using the same are disclosed.

Abstract: Lipid nanoparticle formulations, methods of making, and methods of using same are disclosed.

Abstract: A serial packet sync encoder is used to encode a serial packet sync datastream. In an embodiment, the serial packet sync datastream is made up of the packet sync vector and a unique preamble bit sequence that is preselected. In another embodiment, the serial packet sync datastream is made up of a non-unique bit sequence. A serial packet sync transmitter is used to transmit the serial packet sync datastream. A serial packet sync receiver is provided for receiving the serial packet sync datastream. In an embodiment, the serial packet sync transmitter and the serial packet sync receiver are shift registers. In this way, the serial packet sync datastream can be transmitted and received using only a single pin. The serial packet sync datastream is useful for providing an indication that an event, such as a grant arrival, has occurred. A preamble comparator is provided to compare the received serial packet sync datastream and the preselected preamble to determine if the two match.

Abstract: A system is configured to facilitate bidirectional voice communication between a number of data and/or telephony devices.